Compass Pathfinder Limited

COMPASS Pathways plc is a biotechnology company headquartered in London, United Kingdom, dedicated to accelerating patient access to evidence-based innovation in mental health. The company's core mission is to reimagine mental health care by developing psychedelic medicines to address the significant unmet needs of individuals suffering from mental health conditions for which current treatments are insufficient.

COMPASS Pathways' primary focus is on its investigational COMP360 psilocybin treatment, which is currently in late-stage clinical trials, specifically Phase 3, for treatment-resistant depression (TRD). This proprietary synthetic psilocybin formulation is administered in conjunction with psychological support and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. The company is also exploring COMP360 for other mental health conditions, including post-traumatic stress disorder (PTSD) and anorexia nervosa.

In recent developments, COMPASS Pathways announced in April 2026 that the FDA granted a New Drug Application (NDA) rolling review request and awarded a Commissioner's National Priority Voucher for COMP360 in TRD, which could expedite the review process. The company has also engaged in collaborations with organizations like Osmind and Mindful Health Solutions to inform the development of scalable delivery models for COMP360, if approved. Kabir Nath serves as the Chief Executive Officer, leading the company's efforts to bring this potential transformative treatment to patients.

Latest updates

Compass Pathways Secures FDA Fast Track, Priority Voucher for Psilocybin Treatment

Event summary

  • Compass Pathways received FDA approval for a rolling NDA review of COMP360, its psilocybin formulation for treatment-resistant depression (TRD).
  • The company was selected for the Commissioner's National Priority Voucher (CNPV) program, potentially shortening the NDA review timeline by 1-2 months.
  • COMP360 has demonstrated statistically significant and clinically meaningful results in two Phase 3 clinical trials involving over 1,000 patients.
  • The voucher program provides enhanced communications and a shortened review timeline, while maintaining FDA standards.
  • Approximately 4 million patients in the U.S. are estimated to live with TRD.

The big picture

Compass Pathways' dual wins—the rolling NDA review and the CNPV—represent a significant milestone for the psychedelic-assisted therapy sector, which is still nascent but attracting substantial investment. The FDA’s willingness to expedite review suggests a growing recognition of the unmet need in TRD, but also underscores the potential for broader regulatory shifts in mental health treatment. The CNPV, while beneficial, doesn't negate the inherent risks of drug development and commercialization.

What we're watching

Regulatory Risk
While the CNPV accelerates review, the FDA’s rigorous standards remain, and approval is not guaranteed, potentially exposing the company to significant downside if data fails to meet expectations.
Commercialization
The speed of Compass’ commercial preparations will be critical to capitalize on potential approval, as the treatment’s rapid effect profile requires a novel patient engagement model.
Competitive Landscape
Other companies are pursuing psychedelic therapies for mental health conditions, and Compass’s first-mover advantage may erode if competitors demonstrate superior efficacy or safety profiles.

Compass Pathways Partners with Osmind to Shape Psychedelic Clinic Model

Event summary

  • Compass Pathways has entered a collaboration with Osmind, a platform supporting over 1,000 interventional psychiatry clinics.
  • The partnership aims to inform the operational and clinical readiness of smaller clinics for potential psychedelic treatments, contingent on FDA approval.
  • Osmind’s software and services focus on enabling sustainable, independent psychiatric practices.
  • Compass Pathways’ COMP360 psilocybin treatment has Breakthrough Therapy designation from the FDA and ILAP designation in the UK.

The big picture

Compass Pathways' collaboration with Osmind signals a strategic shift towards proactively shaping the infrastructure for psychedelic treatment delivery, rather than solely focusing on drug development. This move acknowledges the significant operational challenges associated with introducing novel therapies into community-based settings and aims to build a scalable and sustainable model. The partnership leverages Osmind's extensive network of over 1,000 clinics, representing a significant portion of the US interventional psychiatry landscape, to address these challenges.

What we're watching

Regulatory Hurdles
The success of this collaboration hinges on FDA approval of psychedelic treatments, a process with inherent uncertainties and potential delays.
Clinic Adoption
The pace at which independent psychiatric practices adopt and integrate psychedelic treatments will determine the scalability of Compass Pathways' model.
Operational Efficiency
How effectively Osmind’s platform can address the operational burden for clinics will be a key factor in the viability of widespread psychedelic treatment delivery.

Compass Pathways CEO to Address Scaling Challenges at Needham Forum

Event summary

  • Compass Pathways CEO Kabir Nath will participate in a panel discussion at the Needham Virtual Psychedelics Forum on April 27, 2026.
  • The panel's focus is “Clinical Risk, Regulatory Reality and the Path to Scale,” indicating a focus on the hurdles to commercialization.
  • Compass Pathways' lead product, COMP360, has Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression (TRD).
  • A webcast of the event will be available for 30 days following the live session.

The big picture

Compass Pathways' participation in this forum underscores the growing investor interest in psychedelic-assisted therapies, but also signals a heightened awareness of the significant regulatory and clinical hurdles that remain. The company's ability to navigate these challenges and demonstrate a viable path to commercialization will be crucial for sustaining its valuation and fulfilling its ambitious goals in the treatment-resistant depression market. The forum itself suggests a maturing market where discussions are shifting from potential to practical implementation.

What we're watching

Regulatory Headwinds
The panel's discussion of “Regulatory Reality” suggests potential challenges in securing and maintaining approvals for COMP360, which could impact the timeline for commercialization and profitability.
Clinical Risk
Given the focus on clinical risk, investors should monitor the ongoing clinical trial data and any potential safety concerns that could arise, as these could significantly impact the drug’s approval pathway.
Execution Risk
The discussion around “Path to Scale” highlights the operational and logistical challenges Compass Pathways faces in expanding production and distribution, which will be critical for achieving widespread adoption and market penetration.

Compass Pathways Nears Launch as Losses Mount, FDA Meeting Looms

Event summary

  • Compass Pathways reported a net loss of $287.9 million for the full year 2025, compared to $155.1 million in 2024.
  • Research and development expenses remained relatively stable at $118.4 million for 2025.
  • The company anticipates sufficient cash runway to fund operations through 2028 with $149.6 million in cash as of December 31, 2025.
  • Compass is scheduled to meet with the FDA to finalize its NDA submission strategy for COMP360, targeting a launch-ready state by the end of 2026.

The big picture

Compass Pathways is positioned to be a pioneer in the emerging psychedelic-assisted therapy market, but faces significant regulatory and commercial hurdles. The company's financial performance reflects the substantial investment required for clinical trials and regulatory approval, and the looming FDA meeting represents a pivotal moment for its future. The limited adoption of existing TRD treatments suggests a large unmet need, but also highlights the challenges in gaining widespread acceptance of novel therapies.

What we're watching

Regulatory Risk
The FDA meeting's outcome regarding the NDA submission strategy will be critical, as any significant changes could delay the launch timeline and impact investor sentiment.
Commercial Adoption
The pace at which treatment centers integrate COMP360 into their practices will determine the drug’s initial market penetration and revenue generation.
Financial Sustainability
How Compass manages its burn rate and secures additional funding will be essential to maintaining its operational runway beyond 2028.

Compass Pathways Secures $200 Million via Warrant Exercise

Event summary

  • Compass Pathways received approximately $200 million from the exercise of 35,059,448 outstanding warrants issued in January 2025.
  • The company will issue 15,160,619 American Depositary Shares (ADSs) and pre-funded warrants for 19,898,829 ADSs to institutional investors.
  • Proceeds will fund Phase 3 trials for COMP005 and COMP006, Phase 2b/3 trial for COMP360 in PTSD, and commercial readiness activities.
  • Combined with a recent $141 million public offering, Compass Pathways now has sufficient funding to support operations through 2028.

The big picture

Compass Pathways' warrant exercise demonstrates continued investor appetite for psilocybin-based therapies, a nascent but rapidly evolving sector within mental healthcare. The influx of capital allows the company to aggressively pursue clinical trials and commercialization efforts, but also increases scrutiny on their ability to deliver on ambitious timelines and regulatory milestones. The company's reliance on Breakthrough Therapy designation and potential accelerated review pathways highlights the inherent risks associated with novel therapeutic approaches.

What we're watching

Clinical Execution
The success of Compass Pathways hinges on the Phase 3 trials for COMP005, COMP006, and COMP360; any setbacks or delays could significantly impact valuation.
Regulatory Approval
The FDA’s stance on potential accelerated review pathways for COMP360 will be critical, as delays in approval could erode investor confidence.
Capital Needs
While current funding extends to 2028, the company's ability to achieve commercialization and profitability will dictate whether additional capital raises become necessary.

Compass Pathways Raises $150 Million in Public Offering

Event summary

  • Compass Pathways priced a public offering of 17.5 million American Depositary Shares (ADSs) at $8.00 per ADS, raising $150 million in gross proceeds.
  • The offering also includes pre-funded warrants for up to 1.25 million ADSs, sold to institutional investors.
  • Compass Pathways has a 30-day option to issue an additional 2.81 million ADSs.
  • Proceeds will fund ongoing Phase 3 trials for COMP005 and COMP006, Phase 2b/3 trial for COMP360 in PTSD, and general corporate purposes.
  • The offering is expected to close on or about February 20, 2026.

The big picture

Compass Pathways' capital raise underscores the ongoing challenges faced by mental health biotech companies in securing funding, particularly given the high cost and risk associated with clinical trials. The offering's size, while substantial, suggests a degree of investor caution regarding the company's pipeline and the broader market appetite for psilocybin-based therapies. The reliance on Phase 3 trial outcomes highlights the inherent risk in the company's business model.

What we're watching

Clinical Progress
The success of the Phase 3 trials for COMP005, COMP006, and COMP360 will be critical to justifying the valuation and securing potential regulatory approvals, and the use of proceeds is heavily weighted towards these trials.
Shareholder Sentiment
The pricing of the offering at $8.00 per ADS suggests investor concern about the company’s near-term prospects, potentially reflecting uncertainty around clinical trial outcomes and commercialization timelines.
Commercialization
The company's ability to accelerate commercial readiness activities and generate revenue will be key to sustaining investor confidence and justifying the capital raised.

Compass Pathways Seeks $150 Million in Public Offering

Event summary

  • Compass Pathways (CMPS) announced a proposed public offering of $150 million in American Depositary Shares (ADSs).
  • The offering includes a potential additional $22.5 million through underwriters’ options.
  • Jefferies, TD Cowen, Cantor, and Stifel are joint book-runners, with H.C. Wainwright & Co. as lead manager.
  • The offering is made under a shelf registration statement filed with the SEC on May 7, 2025.

The big picture

Compass Pathways' capital raise reflects the ongoing investor interest in psychedelic-assisted therapies for mental health conditions, a sector still in its early stages of commercialization. The $150 million offering provides a significant war chest for the company as it navigates regulatory hurdles and prepares for potential commercial launch of COMP360, but also signals a need for additional funding given the substantial costs associated with clinical trials and market entry.

What we're watching

Market Conditions
The success of the offering hinges on prevailing market conditions, which have been volatile, potentially impacting the final size and pricing.
Regulatory Approval
The FDA’s Breakthrough Therapy designation for COMP360 remains a key driver of investor sentiment, and any delays or setbacks could negatively impact the stock.
Capital Allocation
How Compass Pathways utilizes the raised capital will be crucial; investors will scrutinize whether it accelerates clinical trials or expands commercialization efforts effectively.

Compass Pathways' COMP360 Phase 3 Data Bolsters Regulatory Path for TRD Treatment

Event summary

  • Compass Pathways announced positive top-line results for its Phase 3 COMP006 trial evaluating COMP360 (psilocybin) for treatment-resistant depression (TRD).
  • The trial’s primary endpoint, change in MADRS scores at Week 6, showed a statistically significant reduction (-3.8 points, p<0.001) with a 25mg dose compared to a 1mg control.
  • Combined data from COMP005 and COMP006 suggest durable treatment effects lasting at least 26 weeks with a single or two doses of 25mg COMP360.
  • Compass plans to submit a rolling NDA to the FDA in Q4 2026, following a meeting to discuss the submission process.

The big picture

Compass Pathways’ consistent Phase 3 results represent a significant advancement in the treatment of TRD, a market with limited therapeutic options and a substantial unmet need. The company’s focus on psilocybin-based therapies positions it at the forefront of a nascent wave of psychedelic-assisted treatments, but regulatory and reimbursement hurdles remain substantial. Success hinges on demonstrating a compelling value proposition to both clinicians and payers.

What we're watching

Regulatory Risk
The FDA’s receptiveness to Compass’s proposed rolling NDA submission and potential for accelerated approval will be a key determinant of commercial launch timelines.
Durability Data
The 26-week data from COMP006, expected in early Q3 2026, will be critical in validating the long-term efficacy and potential for reduced retreatment frequency.
Market Adoption
The willingness of payers to reimburse COMP360, given its novel mechanism of action and potential for high cost, will significantly impact market penetration within the TRD patient population.

Compass Pathways to Release Key Phase 3 Data on Psilocybin Treatment

Event summary

  • Compass Pathways (CMPS) will release new clinical data from Phase 3 trials (COMP005 Parts A & B, and COMP006 Part A) for COMP360, a psilocybin formulation, on February 17th at 6:30 am ET.
  • The trials are evaluating COMP360 for treatment-resistant depression (TRD).
  • A live webcast and replay will be available, hosted by Compass management.
  • COMP360 has Breakthrough Therapy designation from the FDA and ILAP designation in the UK.

The big picture

Compass Pathways is at the forefront of a nascent wave of psychedelic-assisted therapies targeting mental health conditions. The company's progress, and the data released tomorrow, will serve as a bellwether for the broader industry, which faces significant regulatory and public perception hurdles. Success for Compass could pave the way for other companies pursuing similar treatments, while failure could dampen enthusiasm for the entire sector.

What we're watching

Clinical Efficacy
The magnitude of the efficacy data released will be critical; modest results could significantly impact investor confidence given the Breakthrough Therapy designation and high expectations.
Regulatory Pathway
The FDA's interpretation of these Phase 3 results will heavily influence the potential for accelerated approval and the timeline for commercialization of COMP360.
Market Adoption
The speed at which clinicians and patients adopt psilocybin-based therapies, even with regulatory approval, will depend on factors including reimbursement and perceived safety profiles.

Compass Pathways Secures FDA Nod for PTSD Trial, Bolsters Depression Pipeline

Event summary

  • The U.S. FDA accepted Compass Pathways' IND application for COMP360 in PTSD, triggering a Phase 2b/3 clinical trial (COMP202).
  • The PTSD trial (COMP202) will enroll patients in a 12-week, double-blinded, controlled study followed by a 40-week open-label extension.
  • Compass amended its term loan facility with Hercules Capital, increasing it to $150 million and extending the maturity date to January 2031.
  • The company plans to disclose Phase 3 trial data (COMP005 and COMP006) in Q1 and Q3 2026, respectively, to facilitate a potential rolling NDA submission for TRD.

The big picture

Compass Pathways' advancement in PTSD treatment reflects the growing recognition of the unmet need in mental health, particularly for conditions with limited therapeutic options. The FDA acceptance validates the company's approach to psychedelic-assisted therapy, but the Phase 2b/3 trial represents a critical inflection point. The amended loan facility provides near-term financial flexibility, but the company's long-term success depends on demonstrating clinical efficacy and securing regulatory approval for both PTSD and TRD.

What we're watching

Clinical Execution
The success of the COMP202 trial hinges on recruitment, retention, and demonstrating efficacy against a challenging placebo effect in PTSD, potentially impacting the timeline for regulatory approval.
Regulatory Pathway
Whether the FDA will permit a rolling NDA submission for TRD, as Compass anticipates, will significantly influence the speed of commercialization and market entry.
Financial Leverage
Compass's ability to draw down the remaining $100 million from the Hercules facility will depend on achieving milestones, and any delays could constrain its operational runway.
CID: 3877